Rinvoq (Upadacitinib) Denied: How to Appeal JAK Inhibitor Denials for RA, PsA, AD, and More

Rinvoq (upadacitinib) is an oral JAK1-selective inhibitor FDA-approved for rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, non-radiographic axial spondyloarthritis, atopic dermatitis, ulcerative colitis, and Crohn's disease. It offers a pill-based alternative to injectable biologics and has shown strong efficacy across its broad indication portfolio. However, Rinvoq carries a class-wide FDA black box warning for serious infections, MACE (major adverse cardiovascular events), thrombosis, and malignancy — and this warning has become a significant tool for insurers to deny coverage.

Why Rinvoq Gets Denied

Black box warning denials. Following the 2021 ORAL Surveillance trial, the FDA added class-wide black box warnings to all JAK inhibitors (including Rinvoq, Xeljanz, and Olumiant) for increased risk of MACE, thrombosis, and malignancy, particularly in patients over 50 with cardiovascular risk factors. Insurers now commonly deny Rinvoq for patients with any cardiovascular history, elevated CVD risk scores, or prior cancer, citing the black box warning as a clinical contraindication. This denial is often overbroad and can be challenged.

Step therapy requirements. For rheumatoid arthritis, insurers require documented failure of at least one conventional DMARD (typically methotrexate) and often one biologic (usually a TNF inhibitor) before approving Rinvoq. For atopic dermatitis, prior failure of topical therapies and often Dupixent is required. For IBD indications, prior TNF failure is typically mandated.

REMS program documentation. Rinvoq is not currently subject to a REMS program per se, but the black box warning language requires patient counseling about risks. Some insurers request documented counseling before approving the drug. Ensure prescriber notes reflect that the patient was counseled on MACE, malignancy, and thrombosis risks.

Off-formulary or tier placement. JAK inhibitors are often placed on high specialty tiers with high cost-sharing, or require a specific coverage exception for patients with the newer indications (AD, axSpA, IBD) that were approved after the initial formulary construction.

Addressing the Black Box Warning in Your Appeal

The FDA black box warning for JAK inhibitors is real but nuanced. Here is how a well-crafted appeal addresses it:

The ORAL Surveillance trial limitations. The study enrolled patients ≥ 50 years old with at least one additional cardiovascular risk factor and compared tofacitinib (Xeljanz) to TNF inhibitors. Applying these findings uniformly to upadacitinib (a different JAK inhibitor), younger patients, patients without cardiovascular risk factors, or patients with non-RA indications (like atopic dermatitis) extends the data well beyond its study population.

Individual risk assessment. The appeal should include a prescriber letter documenting the individual patient's cardiovascular risk profile, thrombosis history, and cancer history — and explaining why, in this specific patient, the clinical benefit of Rinvoq outweighs the risks. For a 35-year-old non-smoker with severe atopic dermatitis and no cardiovascular risk factors, the black box warning has minimal practical applicability.

Lack of adequate alternatives. For patients with multiple-biologic failure history, Rinvoq's oral administration may be the only viable remaining option. When prior injectable biologics have failed or caused serious adverse events, the risk-benefit calculus shifts strongly toward approving Rinvoq.

Step Therapy Documentation

For each indication, document:

• RA: Methotrexate trial (dose, duration, outcome), biologic TNF inhibitor trial(s), reasons for failure
• Atopic dermatitis: Topical corticosteroids and calcineurin inhibitors, systemic agents, Dupixent trial if applicable
• UC/Crohn's: 5-ASA agents (for UC), corticosteroids, immunomodulators, TNF inhibitors
• PsA/AS: NSAIDs, DMARDs, TNF inhibitors

Each failure entry should include specific drug names, doses, dates, and clinical outcome descriptions.

Fight Back With ClaimBack

Rinvoq denials that lean on the black box warning are often legally vulnerable when the patient's actual risk profile doesn't match the trial population. ClaimBack helps you build individualized appeals that address the specific black box warning arguments your insurer is using.

Start your Rinvoq appeal at ClaimBack

Related Reading

• How to Write an Insurance Appeal Letter
• What Is Medical Necessity?
• Internal vs. External Insurance Appeal: What's the Difference?